Analyst Ratings for Cidara Therapeutics (CDTX)
CDTX Rating Summary
CDTX Price Target Summary
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$5.50 (+223.5%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/3/2021 | H.C. Wainwright | Ed Arce | New Coverage | Buy (N/A) |
6.00 (N/A) |
1.45 (1.70) |
17.24% | Details |
| 9/22/2021 | WBB Securities | Stephen Brozak | Upgrade | Strong Buy (Buy) |
6.25 (N/A) |
2.09 (1.70) |
-18.66% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
CDTX Ratings News
- Needham & Company Reiterates Buy Rating, $6 Price Target on Cidara Therapeutics (CDTX)
- Cantor Fitzgerald Reiterates Overweight Rating. $5 Price Target on Cidara Therapeutics (CDTX), "We Believe Street Under-appreciated Sales Potential of CDTX's Two Pipeline Assets"
- Needham & Company Reiterates Buy Rating on Cidara Therapeutics (CDTX)
- See More
